Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service vitreoretinal surgery cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 36 | 3,088 | 14% |
| 2020 | 23 | 2,365 | 15% |
| 2021 | 24 |
Pars plana vitrectomy and retinal detachment repair. Professional codes (what the surgeon bills): CPT 67036, 67040, 67041, 67042, 67108, 67113.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 62% of the cases CMS names in Maryland; 16 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cataract & MIGS | 198 | 39,250−1.2%/yr | −1.2%/yr | 44.00.7× | 91% | 41,300 in 2030+0.8%/yr |
Vitreoretinal surgery in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Texas
| 2024 |
| 2,121 |
| 28% |
| 2025 est. | ≈ 2,110 | – |
| 2026 est. | ≈ 2,170 | – |
| 2,509 |
| 19% |
| 2022 | 22 | 2,162 | 22% |
| 2023 | 29 | 2,234 | 25% |
| 2024 | 30 | 2,121 | 28% |
| 2025 from claims | – | 2,107 1,934–2,229 | 29% |
| 2026 forecast | – | 2,170 1,909–2,504 | 29% |
| 2027 forecast | – | 2,199 1,880–2,620 | 29% |
| 2028 forecast | – | 2,228 1,859–2,728 | 30% |
| 2029 forecast | – | 2,257 1,843–2,830 | 31% |
| 2030 forecast | – | 2,286 1,832–2,930 | 31% |
In 2025, 74% hospital outpatient, 26% surgery center. The share outside the hospital has moved +12 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| −2.9%/yr |
| 2.9 |
| 87% |
| 6,520 in 2030+0.3%/yr |
| Tennessee | 36 | 2,272−2.5%/yr | −2.5%/yr | 3.3 | 77% | 2,320 in 2030+0.3%/yr |
| North Carolina | 33 | 2,261−4%/yr | −4%/yr | 2.3 | 36% | 2,170 in 2030−0.7%/yr |
| Virginia | 28 | 1,985−3.8%/yr | −3.8%/yr | 1.9 | 77% | 2,080 in 2030+0.8%/yr |
| South Carolina | 22 | 1,644−1.1%/yr | −1.1%/yr | 2.4 | 69% | 1,760 in 2030+1.1%/yr |
| Georgia | 19 | 1,497−3.1%/yr | −3.1%/yr | 1.8 | 88% | 1,580 in 2030+0.9%/yr |
| Alabama | 18 | 1,215−6.6%/yr | −6.6%/yr | 2.8 | 45% | 1,170 in 2030−0.7%/yr |
| Louisiana | 14 | 1,034−4.5%/yr | −4.5%/yr | 2.6 | 72% | 980 in 2030−1%/yr |
| Oklahoma | 14 | 1,019−4.8%/yr | −4.8%/yr | 2.1 | 77% | 1,020 in 2030+0.1%/yr |
| Mississippi | 11 | 1,000−1.3%/yr | −1.3%/yr | 2.7 | 72% | 1,010 in 2030+0.2%/yr |
| Kentucky | 16 | 944−6.8%/yr | −6.8%/yr | 2.1 | 85% | 910 in 2030−0.5%/yr |
| Arkansas | 10 | 687−6.8%/yr | −6.8%/yr | 1.8 | 0% | 580 in 2030−2.7%/yr |
| West Virginia | 4 | 208−16%/yr | −16%/yr | 1.0 | 73% | 310 in 2030+6.8%/yr |
| District of Columbia | 3 | 175−2.1%/yr | −2.1%/yr | 2.8 | 51% | 260 in 2030+6.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Alcon leads with 46% of company spending on these surgeons in 2025, −15 pts on 2024.
In 2025, 15 companies reported engagement with Maryland’s surgeons worth $124K in consulting, speaking, meals and travel tied to these products, about $4,135 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 0 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.